Enanta Pharmaceuticals, Inc. (ENTA)

Market: NASD | Currency: USD

Address: 500 Arsenal Street

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative Show more

📈 Enanta Pharmaceuticals, Inc. Historical Chart

📊 Statistics

Analyst 1 Year Price Target: $18.57
Upside/Downside from Analyst Target: 106.35%
Broker Call: 9
Dividend Minimum 3 Year Yield: 0.00%
EPS Growth Range (1Y): 10-25%
Net Income Growth Range (1Y): 10-25%
Revenue Growth Range (1Y): <0%
Upcoming Earnings Date: 2025-12-02
EPS Estimate: -1.05

💰 Dividend History

No dividend history available.

📅 Earnings & EPS History for Enanta Pharmaceuticals, Inc.

Date	Reported EPS
2025-12-01 (estimated upcoming)	-
2025-08-11	-0.85
2025-05-12	-1.06
2025-02-10	-1.05
2024-11-25	-1.36
2024-08-05	-1.07
2024-05-06	-1.47
2024-02-07	-1.58
2023-11-20	-1.33
2023-08-07	-1.86
2023-05-08	-1.79
2023-02-07	-1.39
2022-11-21	-1.27
2022-08-08	-1.53
2022-05-09	-1.63
2022-02-08	-1.48
2021-11-22	-1.22
2021-08-05	-1.19
2021-05-06	-1.09
2021-02-08	-0.41
2020-11-23	-1.46
2020-08-04	-0.71
2020-05-06	-0.3
2020-02-06	0.65
2019-11-21	0.44

📰 Related News & Research

No related articles found for "enanta pharmaceuticals".